BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
Rhea-AI Summary
BioVie (NASDAQ: BIVI) announced that an abstract from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease was accepted for presentation at the American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.
The poster, titled "A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic," will be presented on Monday, April 20, 5:00–6:00 PM CT. Topline results from SUNRISE-PD are expected in mid‑2026. The AAN represents 44,000+ neurology professionals.
Positive
- None.
Negative
- None.
News Market Reaction – BIVI
In the Apr 14 session, BIVI gained 5.80%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.9% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Conference abstract | Positive | -1.4% | SUNRISE-PD abstract acceptance for AD/PD 2026 highlighting baseline demographics. |
| Feb 23 | Investor webinar | Neutral | -0.8% | Announcement of March 4 investor webinar reviewing bezisterim and BIV201 progress. |
| Feb 12 | Conference abstracts | Positive | -3.5% | Two bezisterim posters accepted for American College of Psychiatrists meeting. |
| Jan 08 | Clinical milestone | Positive | -3.7% | Completion of enrollment of 60 patients in Phase 2 SUNRISE-PD trial. |
| Nov 19 | Investor webinar | Neutral | -4.2% | December 9, 2025 investor webinar focused on bezisterim and BIV201 programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and conference-related updates, including SUNRISE-PD milestones and abstract acceptances, have often coincided with modest negative price reactions despite generally constructive operational news.
Over the past several months, BioVie has repeatedly highlighted bezisterim (NE3107) across indications and forums. In January 2026, the company completed enrollment of 60 patients in the Phase 2 SUNRISE-PD trial, followed by multiple abstract acceptances and investor webinars in February–March 2026. These events focused on baseline characteristics, clinical progress, and broader development plans. Despite the operational momentum, each announcement saw small share price declines, underscoring a pattern where informative but non-decisive updates have not translated into positive short-term price reactions.
Key Terms
parkinson’s disease medical
movement disorders medical
neurologists medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026.
The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo1, C Ahlem1, C.L. Reading1, S. O’Quinn2, J. Zhang3, M. Stacy4), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster during the Movement Disorders Session on Parkinson's Disease Emerging Therapeutics, on Monday, April 20, from 5:00 PM–6:00 PM CT.
Topline results from the SUNRISE-PD study are expected in mid‑2026.
The AAN is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with 44,000+ members, the AAN offers access to continuing education, essential practice tools, research grants, networking and advocacy opportunities, and more.
Affiliations: 1BioVie, Inc, 2Perissos, Inc., 3Princeton Pharmatech, 4Medical University of South Carolina
About Bezisterim
Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.
In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid‑2026.
For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.
In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.
In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.
| For Investor Relations Inquiries: | For Media Inquiries: |
| Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com | Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com |
